Antibiotic treatment of animals infected with Borrelia burgdorferi

Clinical Microbiology Reviews

Volumn 22, Issue 3, 2009, Pages 387-395

  Wormser, Gary P ^a   Schwartz, Ira ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; CORTICOSTEROID; DOXYCYCLINE; PENICILLIN G;

ALLOTRANSPLANTATION; ANIMAL DISEASE; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIABILITY; BACTERIUM CULTURE; BORRELIA BURGDORFERI; DOG; DOG DISEASE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; GENETIC VARIABILITY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; LYME DISEASE; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; REVIEW; SEROLOGY; STRAIN DIFFERENCE; TICK BORNE DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; XENODIAGNOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BORRELIA BURGDORFERI; DOGS; HUMANS; LYME DISEASE; MICE; MICROBIAL VIABILITY; MODELS, ANIMAL; TREATMENT OUTCOME;

ANIMALIA; BORRELIA BURGDORFERI;

EID: 67651000062     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00004-09     Document Type: Review

References (54)

1. Aberer, E., A. R. Bergmann, A.-M. Derler, and B. Schmidt. 2007. Course of Borrelia burgdorferi DNA shedding in urine after treatment. Acta Derm. Venereol. 87:39-42.
2. Aguero-Rosenfeld, M. E., G. Wang, I. Schwartz, and G. P. Wormser. 2005. Diagnosis of Lyme borreliosis. Clin. Microbiol. Rev. 18:484-509.
3. Alban, P. S., P. W. Johnson, and D. R. Nelson. 2000. Serum-starvation-induced changes in protein synthesis and morphology of Borrelia burgdorferi. Microbiology 146:119-127.
4. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
5. Asakura, H., M. Watarai, T. Shirahata, and S.-I. Makino. 2002. Viable but nonculturable Salmonella species recovery and systemic infection in morphine-treated mice. J. Infect. Dis. 186:1526-1529.
6. Barer, M. R., and C. R. Harwood. 1999. Bacterial viability and culturability. Adv. Microb. Physiol. 41:94-137.
7. Bigger, J. W. 1944. Treatment of staphylococcal infections with penicillin. Lancet ii:497-500.
8. Bockenstedt, L. K., J. Mao, E. Hodzic, S. W. Barthold, and D. Fish. 2002. Detection of attenuated, non-infectious spirochetes in Borrelia burgdorferi-infected mice after antibiotic treatment. J. Infect. Dis. 186:1430-1437.
9. Bogosian, G., and E. V. Bourneuf. 2001. A matter of bacterial life and death. EMBO Rep. 2:770-774.
10. Cairns, V., and J. Godwin. 2005. Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. Int. J. Epidemiol. 34:1340-1345.
11. del Mar Lleo, M., S. Pieroban, M. C. Tafi, C. Signoretto, and P. Canepari. 2000. mRNA detection by reverse transcription-PCR for monitoring viability over time in an Enterococcus faecalis viable but nonculturable population maintained in a laboratory microcosm. Appl. Environ. Microbiol. 66:4564-4567.
12. Domingo, S., I. Gastearena, A. I. Vitas, I. Lopez-Goni, C. Dios-Vieitez, R. Diaz, and C. Gamazo. 1995. Comparative activity of azithromycin and doxycycline against Brucella sp infection in mice. J. Antimicrob. Chemother. 36:647-656.
13. Feder, H. M. Jr., B. J. B. Johnson, S. O'Connell, E. D. Shapiro, A. C. Steere, G. P. Wormser, and the Ad Hoc International Lyme Disease Group. 2007. A critical appraisal of "chronic Lyme disease." N. Engl. J. Med. 357:1422-1430.
14. Fraser, C. M., S. Casjens, W. M. Huang, G. G. Sutton, R. Clayton, R. Lathigra, O. White, K. A. Kethum, R. Dodson, E. K. Hickey, M. Gwinn, B. Dougherty, J. F. Tomb, R. D. Fleischmann, D. Richardson, J. Peterson, A. R. Kerlavage, J. Quackenbush, S. Salzberg, M. Hanson, R. van Vugt, N. Palmer, M. D. Adams, J. Gocayne, J. Weidman, T. Utterback, L Watthey, L. McDonald, P. Artiach, C. Bowman, S. Garland, C. Fuji, M. D. Cotton, K. Horst, K. Roberts, B. Hatch, H. O. Smith, and J. C. Venter. 1997. Genomic sequence of a Lyme disease spirochete, Borrelia burgdorferi. Nature 390:580-586.
15. Hansen, K., A. Hovmark, A.-M. Lebech, K. Lebech, I. Olsson, L Halkier-Sorensen, E. Olsson, and E. Asbrink. 1992. Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm. Venereol. 72:297-300.
16. Hatcher, S., and B. Arroll. 2008. Assessment and management of medically unexplained symptoms. Br. Med. J. 336:1124-1128.
17. Hodzic, E., S. Feng, K. J. Freet, and S. W. Barthold. 2003. Borrelia burgdorferi population dynamics and prototype gene expression during infection of immunocompetent and immunodeficient mice. Infect. Immun. 71:5042-5055.
18. Hodzic, E., S. Feng, K. Holden, K. J. Freet, and S. W. Barthold. 2008. Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob. Agents Chemother. 52:1728-1736.
19. Hunfeld, K.-P., P. Kraiczy, T. A. Wichelhaus, V. Schafer, and V. Brade. 2000. New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances. Eur. J. Clin. Microbiol. Infect. Dis. 19:27-32.
20. Johnson, R. C., C. B. Kodner, P. J. Jurkovich, and J. J. Collins. 1990. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents. Antimicrob. Agents Chemother. 34:2133-2136.
21. Johnson, R. C., C. Kodner, and M. Russell. 1987. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents. Antimicrob. Agents Chemother. 31:164-167.
22. Johnson, R. C., C. Kodner, M. Russell, and D. Girard. 1990. In vitro and in vivo susceptibility of Borrelia burgdorferi to azithromycin. J. Antimicrob. Chemother. 25(Suppl. A):33-38.
23. Johnson, S. E., G. C. Klein, G. P. Schmid, and J. C. Feeley. 1984. Susceptibility of the Lyme disease spirochete to seven antimicrobial agents. Yale J. Biol. Med. 57:549-553.
24. Kannian, P., G. McHugh, B. J. B. Johnson, R. M. Bacon, L. J. Glickstein, and A. C. Steere. 2007. Antibody response to Borrelia burgdorferi in patients with antibiotic-refractory, antibiotic-responsive or non-antibiotic treated Lyme arthritis. Arthritis Rheum. 56:4216-4225.
25. Kazragis, R. J., L. L. Dever, J. H. Jorgensen, and A. G. Barbour. 1996. In vitro activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites. Antimicrob. Agents Chemother. 40:2632-2636.
26. Klempner, M. S., L. T. Hu, J. Evans, C. H. Schmid, G. M Johnson, R. P. Trevino, D. Norton, D. Wall, J. McCall, M. Kosinski, and A. Weinstein. 2001. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N. Engl. J. Med. 345:85-92.
27. Lee, J., and G. P. Wormser. 2008. Pharmacodynamics of doxycycline for chemoprophylaxis of Lyme disease: preliminary findings and possible implications for other antimicrobials. Int. J. Antimicrob. Chemother. 31:235-239.
28. Lewis, K. 2008. Multidrug tolerance of biofilms and persister cells. Curr. Top. Microbiol. Immunol. 322:107-131.
29. Luft, B. J., D. J. Volkman, J. J. Halperin, and R. J. Dattwyler. 1988. New chemotherapeutic approaches in the treatment of Lyme borreliosis. Ann. N. Y. Acad. Sci. 539:352-361.
30. Malawista, S. E., S. W. Barthold, and D. Persing. 1994. Fate of Borrelia burgdorferi DNA in tissues of infected mice after antibiotic treatment. J. Infect. Dis. 170:1312-1316.
31. Moody, K. D., R. L. Adams, and S. W. Barthold. 1994. Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice. Antimicrob. Agents Chemother. 38:1567-1572.
32. Mursic, V. P., B. Wilske, G. Schierz, M. Holmburger, and E. Süss. 1987. In vitro and in vivo susceptibility of Borrelia burgdorferi. Eur. J. Clin. Microbiol. 6:424-426.
33. Nocton, J. J., F. Dressler, B. J. Rutledge, P. N. Rys, D. H. Persing, and A. C. Steere. 1994. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N. Engl. J. Med. 330:229-234.
34. Nystrom, T. 2003. Nonculturable bacteria: programmed survival forms or cells at death's door. BioEssays 25:204-211.
35. Pahl, A., U. Kuhlbrandt, K. Brune, M. Rollinghoff, and A. Gessner. 1999. Quantitative detection of Borrelia burgdorferi by real-time PCR. J. Clin. Microbiol. 37:1958-1963.
36. Pankey, G. A., and L. D. Sabath. 2004. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin. Infect. Dis. 38:864-870.
37. Patel, I. H., and S. A. Kaplan. 1984. Pharmacokinetic profile of ceftriaxone in man. Am. J. Med. 77(4C):17-25.
38. Pavia, C., M. A. Inchiosa, Jr., and G. P. Wormser. 2002. Efficacy of shortcourse ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice. Antimicrob. Agents Chemother. 46:132-134.
39. Philipp, M. T., L. C. Bowers, P. T. Fawcett, M. B. Jacobs, F. T. Liang, A. R. Marques, P. D. Mitchell, J. E. Purcell, M. S. Retterree, and R. K. Straubinger. 2001. Antibody response to IR6, a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of Borrelia burgdorferi infection in experimental animals and in humans. J. Infect. Dis. 184:870-878.
40. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, M. Freudenberg, M., Ricciardi-Castagnoli, P., B. Layton, and B. Beutler. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088.
41. Preac-Mursic, V., W. Marget, U. Busch, D. Pleterski Rigler, and S. Hagl. 1996. Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis. Infection 24:9-16.
42. Preac-Mursic, V., B. Wilske, G. Schierz, E. Suss, and B. Gross. 1989. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi. Eur. J. Clin. Microbiol. Infect. Dis. 8:651-653.
43. Rice, K. C., and K. W. Bayles. 2008. Molecular control of bacterial death and lysis. Microbiol. Mol. Biol. Rev. 72:85-90.
44. Saivin, S., and G. Houin. 1988. Clinical pharmacokinetics of doxycycline and minocycline. Clin. Pharmacokinet. 15:355-366.
45. Shapiro, E. D., R. Dattwyler, R. B. Nadelman, and G. P. Wormser. 2005. Response to meta-analysis. Int. J. Epidemiol. 34:1437-1439.
46. Steere, A. C., and S. M. Angelis. 2006. Therapy for Lyme arthritis. Strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum. 54:3079-3086.
47. Straubinger, R. K. 2000. PCR-based quantifications of Borrelia burgdorferi organisms in canine tissue over a 500-day postinfection period. J. Clin. Microbiol. 38:2191-2199.
48. Straubinger, R. K., A. F. Straubinger, B. S. Summers, and R. H. Jacobson. 2000. Status of Borrelia burgdorferi infection after antibiotic treatment and the effects of corticosteroids: an experimental study. J. Infect. Dis. 181:1069-1081.
49. Straubinger, R. K., B. A. Summers, Y.-F. Chang, and M. J. G. Appel. 1997. Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J. Clin. Microbiol. 35:111-116.
50. Tsiodras, S., G. Samonis, D. T. Boumpas, and D. P. Kontoyiannis. 2008. Fungal infections complicating tumor necrosis alpha blockade therapy. Mayo Clin. Proc. 83:181-194.
51. Wormser, G. P., S. W. Barthold, E. D. Shapiro, R. J. Dattwyler, J. S. Bakken, A. C. Steere, L. K. Bockenstedt, and J. D. Radolf. 2007. Anti-tumor necrosis factor-α activation of Borrelia burgdorferi spirochetes in antibiotic-treated murine Lyme borreliosis: an unproven conclusion. J. Infect. Dis. 196:1865-1866.
52. Wormser, G. P., R. J. Dattwyler, E. D. Shapiro, J. J. Halperin, A. C. Steere, M. S. Klempner, P. J., Krause, J. S. Bakken, F. Strle, G. Stanek, L. Bockenstedt, D. Fish, J. S. Dumler, and R. D. Nadelman. 2006. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 43:1089-1134.
53. Yrjanainen, H., J. Hytonen, K.-O. Soderstrom, J. Oksi, K. Hartiala, and M. K. Viljanen. 2006. Persistent joint swelling and borrelia-specific antibodies in Borrelia garinii-infected mice after eradication of vegetative spirochetes with antibiotic treatment. Microbes Infect. 8:2044-2051.
54. Yrjanainen, H., J. Hytonen, X. Y. Song, J. Oksi, K. Hartiala, and M. K. Viljanen. 2007. Anti-tumor necrosis factor-α treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice. J. Infect. Dis. 195:1489-1496.